Journal

Atman's cardiovascular AI design separates conversation from a deterministic clinical engine. Examine where that architecture could help and which errors it cannot eliminate by its...

Ask Revive brings AI into employer-linked benefits and care navigation. Distinguish available services from clinical recommendations, and examine handover, transparency and continu...

Dimer Health's AiME links patient questions with discharge information and a clinical team. Its value depends on escalation, reconciliation and the whole transitional-care service.

Hello Patient's Converse Health acquisition extends AI into chart-driven follow-up. Examine conditional instructions, clinical ownership and what a completed booking does not prove...

Abridge announced VA contract selection and a University of Texas agreement in autumn 2026. Explore what contract ceilings, systemwide access and local implementation tell us, and ...

Augnito Omni moves from dictated notes towards ambient clinical documentation. Examine the advertised workflow, coding boundaries, language and specialty fit, and the practical sig...

Pippen AI targets Canadian family medicine with notes, referral letters, clinical insights and billing suggestions. Explore how to assess a multi-problem encounter, local workflow ...

Abridge Assistant can pre-fill clinical calculators from chart information. Explore provenance, timestamps, conflicting records and why a correct formula does not make an unchecked...

Abridge announced pre-bill review for CDI and coding teams on 14 September 2026. Examine how clinical meaning reaches the claim, where human control remains and what evidence would...

MEDFAR acquired AlloMia on 14 October 2026, bringing AI call handling into MYLE. Examine the reported pilot results, patient handover and what clinics should measure beyond the num...

Abridge Assistant brings chart context, cited evidence and draft clinical documents into one workflow. Explore the benefits, review boundaries and questions clinicians should ask b...

Healthcare AI expansion depends on local financing, clinical pathways, data access and regulation, not simply translating a successful US product.